IncellDx, Inc.
16Patents
16Active
16Granted
50Portfolio score
Filing activity: Feb 24, 2009 → Jun 16, 2023 · 2 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7888032B2 | HPV E6, E7 mRNA assay and methods of use thereof | Chemistry; Metallurgy | 13 | Active |
| US8653250B2 | HPV E6, E7 MRNA assay and methods of use thereof | Chemistry; Metallurgy | 3 | Active |
| US11180491B2 | Method of treating COVID-19 by administering the CCR5/CCL5 (RANTES) interaction inhibitor maraviroc | Emerging Cross-Sectional Technologies | 1 | Active |
| US10782298B2 | Methods of detecting per cell PD-L1 expression and uses thereof | Physics | 1 | Active |
| US10627389B2 | Methods of assessing cellular breast samples and compositions for use in practicing the same | Physics | 1 | Active |
| US10167526B2 | Methods and systems for predicting whether a subject has a cervical intraepithelial neoplasia (CIN) lesion from a suspension sample of cervical cells | Chemistry; Metallurgy | 0 | Active |
| US11988658B2 | Methods of assessing cellular breast samples and compositions for use in practicing the same | Physics | 0 | Active |
| US10011884B2 | Methods and systems for predicting whether a subject has a cervical intraepithelial neoplasia (CIN) lesion from a suspension sample of cervical cells | Chemistry; Metallurgy | 0 | Active |
| US11402391B2 | Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist | Physics | 0 | Active |
| US10308990B2 | Methods of evaluating a cellular sample for latent cellular replication competent HIV-1 | Chemistry; Metallurgy | 0 | Active |
| US9464332B2 | HPV E6, E7 MRNA assay and methods of use thereof | Chemistry; Metallurgy | 0 | Active |
| US11726089B2 | Methods of assaying neoplastic and neoplasia-related cells and uses thereof | Physics | 0 | Active |
| US12298309B2 | Methods of assaying neoplastic and neoplasia-related cells and uses thereof | Physics | 0 | Active |
| US11629196B2 | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions | Emerging Cross-Sectional Technologies | 0 | Active |
| US11952373B2 | Method of treating hypercytokinemia by administering the CCR5/CCL5 (RANTES) interaction inhibitor maraviroc | Emerging Cross-Sectional Technologies | 0 | Active |
| US12228580B2 | Methods of assigning a COVID pathological type based on a cytokine/chemokine panel | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.